Clinical Trial Update: Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of enzalutamide in metastatic castration-resistant prostate cancer completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-07-05